INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rafael Holdings, Inc.

Rafael Holdings said its Cyclo Therapeutics subsidiary’s Phase 3 TransportNPC study of Trappsol Cyclo in 94 patients did not achieve statistical significance on the primary endpoint. Rafael shares fell $0.71, or 34.98%, to $1.32 on September 30, 2026. Pomerantz LLP is investigating whether Rafael and certain officers or directors engaged in securities fraud or other unlawful business practices; these are allegations under investigation.

Analysis

The incremental signal is scientific, not legal: the pivotal study miss challenges the value of the Cyclo Therapeutics program, while a law-firm investigation announcement is not evidence that misconduct occurred or that a viable claim will be filed. The sharp repricing may already capture much of the immediate disappointment; the next leg depends on whether the full dataset, secondary endpoints, or regulatory feedback offers a credible path forward. For Rafael, the key transmission is potential impairment of the subsidiary’s contribution to parent-level asset value and, if the program was important to funding plans, reduced strategic flexibility. The magnitude cannot be assessed without Rafael’s ownership/economic exposure, cash and liabilities, other asset values, and the subsidiary’s funding needs. Over 1–3 months, full data and any regulatory or company update are the catalysts; over 6–18 months, the issue is whether the program can be rescued, redesigned, partnered, or discontinued. A contrarian risk is treating the investigation headline as a fresh fundamental shock: it may add little absent a filed complaint or material evidence. Conversely, a rebound based on secondary endpoints alone may overstate recovery if the primary endpoint miss leaves no credible regulatory route.

Key Decisions for Investors

• Do not short solely on the Pomerantz announcement or chase the initial gap lower. Treat the investigation as unproven and likely secondary to the trial result unless a complaint, substantive allegations, or a material company disclosure emerges.
• Maintain a bearish-to-neutral bias on RFL pending the full study dataset and regulatory path. If options are liquid and pricing permits, consider a defined-risk put spread rather than an outright short; avoid assigning a price target without verified asset and balance-sheet data.
• Before sizing, verify Rafael’s economic exposure to Cyclo Therapeutics, consolidated cash and liabilities, the subsidiary’s runway, and the value and liquidity of other assets. These determine whether the clinical setback translates into parent-level solvency or valuation pressure.
• Reassess on the full data and any regulator interaction. The downside thesis weakens if independently reviewable results support a credible path to approval or a partner commits capital; it strengthens if management discontinues the program, funding needs rise, or guidance/asset disclosures indicate material impairment.